Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03415243 · ClinicalTrials.gov registry record · Phase 1
To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03415243 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 28 participants.
The verdict
NCT03415243, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This clinical study will be conducted to characterize the gastrointestinal transit of two multi-symptoms formulations by inclusion of a radiolabel marker.
Interventions
- DRUG Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg
- DRUG Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2018-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03415243
The ClinicalTrials.gov registry entry for NCT03415243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg is the first listed.
NCT03415243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03415243 about?
NCT03415243 is a clinical study titled "To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers". This clinical study will be conducted to characterize the gastrointestinal transit of two multi-symptoms formulations by inclusion of a radiolabel marker.
What is the current status of trial NCT03415243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2018-03-01. Estimated completion is 2018-03-29.
What interventions are being tested in trial NCT03415243?
The interventions under investigation include: Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg (DRUG), Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg (DRUG).
Who is sponsoring clinical trial NCT03415243?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.